Physician profile
Peter H Pak
NPI 1205833811
$3,476.02
in general payments reported to CMS, 2019-2025
31 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,190 · 2020: $293 · 2021: $112 · 2022: $100 · 2023: $390 · 2024: $1,179 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056 · Travel and Lodging: $725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.38 |
| Travel and Lodging | $724.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $724.89 | 2024 | |
| Novartis Pharmaceuticals Corporation | $373.90 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $371.58 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $340.41 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $246.54 | 2019-2023 | Repatha |
| Impulse Dynamics (USA) INC. | $170.77 | 2024 | Optimizer |
| Pfizer INC. | $160.81 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $139.98 | 2019-2025 | Farxiga |
| Cvrx, INC. | $120.65 | 2023 | Barostim Neo System |
| Akcea Therapeutics, INC. | $106.82 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $93.30 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.61 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $83.40 | 2019-2024 | |
| Aroa Biosurgery Incorporated | $74.02 | 2024 | |
| Teleflex LLC | $59.49 | 2024 | Quikclot |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $36.88 | 2019 | |
| Inspire Medical Systems, INC. | $32.50 | 2025 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.84 | 2021-2023 | Lifevest |
| Medtronic, INC. | $27.72 | 2023 | Signia |
| Edwards Lifesciences Corporation | $26.22 | 2019 | |
| Kestra Medical Technology Services, INC. | $21.47 | 2025 | Assure Wcd |
| Recor Medical INC | $20.76 | 2024 | Paradise Renal Denervation System |
| Bardy Diagnostics, INC. | $18.61 | 2020 | |
| Abbott Laboratories | $16.75 | 2021 | |
| Scpharmaceuticals INC. | $16.09 | 2024 | |
| Baxter Healthcare | $15.52 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $15.48 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.22 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $14.15 | 2019 | |
| Tactile Systems Technology INC | $12.64 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Pak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.